Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01973881 · ClinicalTrials.gov registry record
Quantitative MRI for Myelofibrosis
A clinical trial of Myelofibrosis, sponsored by University of Michigan Rogel Cancer Center.
- Recruiting
- Registry status
- 192
- Enrollment target
- 1
- Study location
NCT01973881 is a study of Myelofibrosis that is actively recruiting participants, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 192 participants, roughly in line with the 193-participant average among 61 other Myelofibrosis trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT01973881, a study of Myelofibrosis, is actively recruiting participants, sponsored by University of Michigan Rogel Cancer Center.
- RECRUITING
- Registry status
- 192 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
Conditions Studied
Interventions
- PROCEDURE T1 Weighted MRI (magnetic resonance imaging)
Study Locations (1)
Michigan
- University of Michigan Hospital - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 192 participants |
| Start Date | 2014-12-22 |
| Est. Completion | 2026-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01973881
The ClinicalTrials.gov registry entry for NCT01973881 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 192 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 193-participant average among 61 other Myelofibrosis trials with a reported enrollment target. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which T1 Weighted MRI (magnetic resonance imaging) is the first listed.
NCT01973881 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT01973881 about?
NCT01973881 is a clinical study titled "Quantitative MRI for Myelofibrosis". This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
What is the current status of trial NCT01973881?
This trial is currently recruiting. The enrollment target is 192 participants. The study started on 2014-12-22. Estimated completion is 2026-12.
What conditions does trial NCT01973881 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT01973881?
The interventions under investigation include: T1 Weighted MRI (magnetic resonance imaging) (PROCEDURE).
Who is sponsoring clinical trial NCT01973881?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01973881 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Oral Nuvisertib (TP-3654) in Patients With Myelofibrosis
RECRUITING · Phase 1
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Study of Navtemadlin add-on to Ruxolitinib in JAK Inhibitor-Naïve Patients With Myelofibrosis Who Have a Suboptimal Response to Ruxolitinib
RECRUITING · Phase 3
-
Momelotinib During and After HCT in Myelofibrosis
RECRUITING · Phase 1
-
A Study of Ruxolitinib in Combination With Ulixertinib in People With Myelofibrosis
RECRUITING · Phase 1
-
Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.